SELLAS Life Sciences Group (SLS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.70B and a free-cash-flow yield of -3.1%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 4.1/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Leading · +598.1% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-47.0%
How far the last close sits under the highest price of the past five years.
Market cap
$1.70B
Trailing P/E
—
Price / book
12.4
Price / sales
—
FCF yield
-3.1%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
-100.0%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
2.6
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
SLS earnings
Next report: Nov 11, 2026 (Q3 2026, EPS estimate -$0.05).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 11, 2026
-$0.05
-$0.04
-25.0%
$0
Q4 2025
Mar 19, 2026
-$0.05
-$0.06
+16.7%
$0
Q3 2025
Nov 12, 2025
-$0.06
-$0.08
+25.0%
$0
Q2 2025
Aug 12, 2025
-$0.07
-$0.08
+12.5%
$0
SLS analyst price target
Median target $32.50 from 2 analysts, ranging $30.00 – $35.00.
Nama's AI scorecard currently rates SELLAS Life Sciences Group Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SLS report earnings?
SELLAS Life Sciences Group's next scheduled report is on Nov 11, 2026. Analysts expect EPS of -$0.05.
What is the SLS price target?
The median analyst price target from 2 analysts is $32.50, with a range of $30.00 – $35.00.
Is SLS Shariah compliant?
Nama's AAOIFI-style screen reads SELLAS Life Sciences Group as Can't Tell. A figure the screen needs is missing, so it can't tell.